OnCo
drugsTreatmentPhase 2

Anvumetostat

aka MTA Cooperative PRMT5 inhibitor, AMG 193

Anvumetostat is an experimental small-molecule drug from Amgen in phase 2 trials for non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).